Cumberland Pharmaceuticals Inc. (CPIX)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
CPIX Insider Trading Activity
CPIX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $38,388 | 232 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Krogulski Kenneth | director | 58 | $26,663 | 0 | $0 | $26,663 |
| Jones James | director | 58 | $4,900 | 0 | $0 | $4,900 |
| KAZIMI A J | Chairman and CEO | 58 | $4,900 | 0 | $0 | $4,900 |
| Young Caroline | director | 58 | $1,925 | 0 | $0 | $1,925 |
About Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Insider Activity of Cumberland Pharmaceuticals Inc.
Over the last 12 months, insiders at Cumberland Pharmaceuticals Inc. have bought $38,388 and sold $0 worth of Cumberland Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Cumberland Pharmaceuticals Inc. have bought $82,175 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Krogulski Kenneth (director) — $26,663. Jones James (director) — $4,900. KAZIMI A J (Chairman and CEO) — $4,900.
The last purchase of 39 shares for transaction amount of $92 was made by KAZIMI A J (Chairman and CEO) on 2024‑12‑20.
List of Insider Buy and Sell Transactions, Cumberland Pharmaceuticals Inc.
| 2024-12-20 | KAZIMI A J | Chairman and CEO | 39 0.0003% | $2.35 | $92 | +95.37% | ||
| 2024-12-20 | Krogulski Kenneth | director | 301 0.0022% | $2.35 | $707 | +95.37% | ||
| 2024-12-20 | Jones James | director | 39 0.0003% | $2.35 | $92 | +95.37% | ||
| 2024-12-20 | Young Caroline | director | 2 <0.0001% | $2.35 | $5 | +95.37% | ||
| 2024-12-19 | KAZIMI A J | Chairman and CEO | 40 0.0003% | $2.33 | $93 | +89.66% | ||
| 2024-12-19 | Krogulski Kenneth | director | 266 0.0018% | $2.33 | $620 | +89.66% | ||
| 2024-12-19 | Jones James | director | 40 0.0003% | $2.33 | $93 | +89.66% | ||
| 2024-12-19 | Young Caroline | director | 4 <0.0001% | $2.33 | $9 | +89.66% | ||
| 2024-12-18 | KAZIMI A J | Chairman and CEO | 49 0.0003% | $2.19 | $107 | +86.54% | ||
| 2024-12-18 | Krogulski Kenneth | director | 312 0.002% | $2.19 | $683 | +86.54% | ||
| 2024-12-18 | Jones James | director | 49 0.0003% | $2.19 | $107 | +86.54% | ||
| 2024-12-18 | Young Caroline | director | 10 <0.0001% | $2.19 | $22 | +86.54% | ||
| 2024-12-17 | KAZIMI A J | Chairman and CEO | 49 0.0003% | $2.12 | $104 | +104.25% | ||
| 2024-12-17 | Krogulski Kenneth | director | 312 0.0022% | $2.12 | $661 | +104.25% | ||
| 2024-12-17 | Jones James | director | 49 0.0003% | $2.12 | $104 | +104.25% | ||
| 2024-12-17 | Young Caroline | director | 10 <0.0001% | $2.12 | $21 | +104.25% | ||
| 2024-12-16 | KAZIMI A J | Chairman and CEO | 49 0.0004% | $2.21 | $108 | +104.25% | ||
| 2024-12-16 | Krogulski Kenneth | director | 312 0.0023% | $2.21 | $690 | +104.25% | ||
| 2024-12-16 | Jones James | director | 49 0.0004% | $2.21 | $108 | +104.25% | ||
| 2024-12-16 | Young Caroline | director | 10 <0.0001% | $2.21 | $22 | +104.25% |
Insider Historical Profitability
| KAZIMI A J | Chairman and CEO | 5702296 40.8228% | $23.55M | 345 | 1 | <0.0001% |
| Krogulski Kenneth | director | 276343 1.9783% | $1.14M | 361 | 0 | <0.0001% |
| Jones James | director | 40146 0.2874% | $165,802.98 | 240 | 0 | <0.0001% |
| Young Caroline | director | 29818 0.2135% | $123,148.34 | 351 | 0 | <0.0001% |
| Greer Lawrence W | director | 496435 3.554% | $2.05M | 0 | 2 | |
| Marstiller Jean W | Sr. VP & Corp. Secretary | 428198 3.0655% | $1.77M | 0 | 2 | |
| Edwards Robert | director | 400970 2.8706% | $1.66M | 1 | 1 | <0.0001% |
| Cearnal Martin E | Sr VP/Chief Commercial Officer | 178473 1.2777% | $737,093.49 | 172 | 0 | <0.0001% |
| JACOBS JOEY A | director | 88415 0.633% | $365,153.95 | 38 | 0 | <0.0001% |
| Galante Joseph C | director | 57356 0.4106% | $236,880.28 | 304 | 0 | <0.0001% |
| Pavliv Leo | Sr. Vice President, Operations | 26445 0.1893% | $109,217.85 | 1 | 1 | <0.0001% |
| Bonner Michael | Chief Financial Officer | 18454 0.1321% | $76,215.02 | 9 | 0 | <0.0001% |
| Griggs Jonathan | director | 10803 0.0773% | $44,616.39 | 0 | 1 | |
| Hamm John M. | Chief Financial Officer | 6800 0.0487% | $28,084.00 | 1 | 0 | +6.25% |
| Lawrence Thomas R | director | 0 0% | $0 | 0 | 16 | |
| Bernard Gordon R | director | 0 0% | $0 | 0 | 78 |
Historical Insider Profitability vs. Competitors
Cumberland Pharmaceuticals Inc. (CPIX) | $2,051,022 | 1591 | -12.84% | $57.69M |
$22,899,264 | 81 | 34.90% | $25.02M | |
$218,350,131 | 64 | 16.68% | $318.54M | |
$125,860,243 | 57 | -4.48% | $40.87M | |
$2,740,482 | 50 | 9.37% | $39.37M | |
$30,209,812 | 45 | -1.91% | $12.11M | |
$6,453,272 | 41 | -4.22% | $20.73M | |
$6,021,989 | 30 | -0.17% | $317.38M | |
$3,140,759 | 30 | 10.79% | $13.74M | |
$423,174,478 | 29 | -7.58% | $38.5M | |
$17,389,773 | 25 | -6.03% | $290.7M | |
$1,507,654 | 22 | -23.16% | $92.54M | |
$25,034,841 | 20 | 9.38% | $233.64M | |
$32,330,336 | 13 | -9.80% | $12.96M | |
$758,061 | 9 | 60.08% | $123.67M | |
$4,039,981 | 8 | -49.09% | $11.11M | |
$179,515 | 7 | 1.51% | $267.34M | |
$103,523 | 3 | 9.40% | $69.04M | |
$5,003,136 | 1 | -14.58% | $252.88M |
CPIX Institutional Investors: Active Positions
| Increased Positions | 4 | +12.9% | 19,709 | +0.96% |
| Decreased Positions | 12 | -38.71% | 221,483 | -10.84% |
| New Positions | <1 | New | 437 | New |
| Sold Out Positions | 3 | Sold Out | 13,152 | Sold Out |
| Total Postitions | 23 | -25.81% | 2M | -9.87% |
CPIX Ownership Change vs Market
Institutional Investor Ownership
| Renaissance Technologies Llc | $2,328.00 | 3.62% | 507,163 | -21,000 | -3.98% | 2024-12-31 |
| Vanguard Group Inc | $1,718.00 | 2.67% | 374,251 | 0 | 0% | 2024-12-31 |
| Dimensional Fund Advisors Lp | $1,253.00 | 1.95% | 272,969 | -11,036 | -3.89% | 2024-12-31 |
| Acadian Asset Management Llc | $864.00 | 1.34% | 188,164 | 0 | 0% | 2024-12-31 |
| Bridgeway Capital Management, Llc | $845.00 | 1.32% | 184,155 | -102,500 | -35.76% | 2024-12-31 |
| Bank Of New York Mellon Corp | $345.00 | 0.54% | 75,269 | +<1 | +<0.01% | 2024-12-31 |
| Geode Capital Management, Llc | $341.00 | 0.53% | 74,305 | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $195.00 | 0.3% | 42,581 | -67,487 | -61.31% | 2024-12-31 |
| Two Sigma Investments, Lp | $173.00 | 0.27% | 37,649 | +18,271 | +94.29% | 2024-12-31 |
| State Street Corp | $155.00 | 0.24% | 33,700 | 0 | 0% | 2024-12-31 |